Brief: Coya Therapeutics Inc Announces Positive Results From A Proof-Of-Concept Academic Clinical Study For Coya 302 In Amyotrophic Lateral Sclerosis (Als)
21/03/2023 11:31
March 21 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS, INC. ANNOUNCES POSITIVE RESULTS FROM A
PROOF-OF-CONCEPT ACADEMIC CLINICAL STUDY FOR COYA 302 IN
AMYOTROPHIC LATERAL SCLEROSIS (ALS)
* COYA THERAPEUTICS, INC. ANNOUNCES POSITIVE RESULTS FROM A
PROOF-OF-CONCEPT ACADEMIC CLINICAL STUDY FOR COYA 302 IN
AMYOTROPHIC LATERAL SCLEROSIS (ALS)
* COYA THERAPEUTICS INC - COYA 302 APPEARED TO BE WELL
TOLERATED
IN ALL STUDY PATIENTS
* COYA THERAPEUTICS INC - PLAN TO FILE AN IND WITH FDA IN
SECOND
HALF OF 2023 AND INITIATE A CLINICAL STUDY SOON THEREAFTER
* COYA THERAPEUTICS INC - NO PATIENT DISCONTINUED STUDY, AND
NO
DEATHS OR OTHER SERIOUS ADVERSE EVENTS WERE REPORTED
* COYA THERAPEUTICS INC - MOST COMMON ADVERSE EVENT WAS MILD
INJECTION-SITE REACTIONS
Source text for Eikon: ID:nBw3D2Ssqa
Further company coverage: COYA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)